%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Dry Eye News
10/30/2026
BreakingCornealDry EyeGlaucomaIOLLaserPremiumPresbyopiaRetinaRevenue
Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz
Bausch + Lomb reported Oct. 28 that its Q3-2026 revenue totaled $1.4 billion, a 7 percent increase (+8 percent cc) from $1.3 billion in Q3-2025. Ophthalmic pharmaceuticals segment revenue was $367 ...
10/30/2026
BreakingDry EyeStudy
Researchers Develop New Standardized Grading System for MGD
A study published Oct. 6 in Clinical Optometry introduces the Meibomian Gland Composite Score (MGCS)—a standardized grading system that could help clinicians more precisely track meibomian gland dy...
10/30/2026
BreakingCornealDry EyeRegulation
Stuart Submits IND Amendment to US FDA for Trial of ST-100 in Corneal Wound Healing
Stuart Therapeutics announced Oct. 9 that it had submitted an investigational new drug application (IND) amendment to the US FDA to study its lead candidate, ST-100 (vezocolmitide) eye drops, in co...
10/21/2026
Dry EyeNewsletterPharmaRevenue
Miticides to Treat Dry Eye Climbing Toward $1 Billion in Annual Sales
Tarsus Pharmaceuticals is behind the rapid growth of the miticide category of dry-eye related pharmaceuticals in the US. Market Scope expects US sales in the miticide category to soon exceed $1 bil...
10/21/2026
Dry EyeNewsletterRegulation
Aldeyra to File Formal Dispute with US FDA over Reproxalap Rejection
Aldeyra Therapeutics reported Sept. 29 that it would submit a formal dispute resolution request with the US FDA over the rejection of reproxalap, a topical treatment candidate for dry eye disease. ...
10/21/2026
AICataractDiagnosticDigitalDry EyeEmergingIOLMyopiaNewsletterOculomicsRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, October 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
10/2/2026
BreakingDry EyePharmaRegulation
Aldeyra to File Formal Dispute with US FDA over Reproxalap Rejection
Aldeyra Therapeutics reported Sept. 29 that it would submit a formal dispute resolution request with the US FDA over the rejection of reproxalap, a topical treatment candidate for dry eye disease. ...
9/25/2026
AllergyBreakingDry EyeRegulation
UK Pet Food Company Concludes Recall After Reports of Sudden Dry Eye Symptoms in Dogs
The Years pet food company, based in the UK, has concluded a recall of all its fresh pet food products after an independent investigation found no link between its ingredients and dog owners’ repor...
9/22/2026
Dry EyeNewsletter
Ophthalmologist Urges Early Intervention in Dry Eye Management to Avoid Surprises
Jason Bacharach, MD, of North Bay Eye Associates in northern California, has a word of advice for ophthalmologists and optometrists. Four words, actually: interventional dry eye management (IDEM). ...
9/22/2026
DeviceDry EyeGlaucomaMyopiaNewsletterRegulation
Select US FDA Approvals and Clearances in August 2026
The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in August 2026, according to the agency’s database. Sight Sciences received clearance for a label...
9/22/2026
CornealDealsDry EyeFundingNewsletterPharmaPresbyopiaRefractiveRetina
Ingenia Leads Latest Fundraising with $42.3 Million Initial Public Offering
Ingenia Therapeutics led recent ophthalmic fundraising efforts, which totaled $57.3 million in the past four weeks.
9/22/2026
Dry EyeNewsletterPharmaRefractive
Bausch + Lomb Advancing Dual-Action Dry Eye Drop, Ocular Surface Pain Candidate
Bausch + Lomb reported Aug. 24 that it would advance two of its topical ocular pipeline candidates based on clinical trial results. The company’s dual-action dry eye drop candidate—combining lifite...
9/22/2026
AIChinaDealsDry EyeEuropeGlaucomaIOLIndustryLow VisionMyopiaNewsletterPharmaPresbyopiaRetinaSurgical
September 2026 Ophthalmic News Briefs
UK-based Rayner reported Sept. 7 the launch of its Galaxy Hydrophobic spiral IOL. The lens will be available commercially in the EU in Q4-2026. The original Galaxy spiral IOL, a full range of visio...
9/4/2026
BreakingDiagnosticDry Eye
Ophthalmologist Urges Early Intervention in Dry Eye Management to Avoid Surprises
Jason Bacharach, MD, of North Bay Eye Associates in northern California, has a word of advice for ophthalmologists and optometrists. Four words, actually: interventional dry eye management (IDEM). ...
8/28/2026
BreakingClinical TrialDry EyePharma
Bausch + Lomb Advancing Dual-Action Dry Eye Drop, Ocular Surface Pain Candidate
Bausch + Lomb reported Aug. 24 that it would advance two of its topical ocular pipeline candidates based on clinical trial results. The company’s dual-action dry eye drop candidate—combining lifite...
8/21/2026
BreakingDeviceDry EyeRegulation
TearCare Label Expanded to Include Improvement of Meibomian Gland Function
Sight Sciences reported Aug. 19 that the US FDA had expanded the labeling for the TearCare thermal expression device to include improvement of meibomian gland function in adult patients with evapor...
8/20/2026
DealsDry EyeNewsletterPharma
Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye
Harrow, of Nashville, Tennessee, announced Aug. 6 that it would acquire global rights to Tyrvaya (varenicline) nasal spray for dry eye from Viatris. Under the deal, Harrow will pay $30 million up f...
8/20/2026
CataractChinaClinical TrialCornealDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIOLNewsletterPharmaRetinaSurgical
Tarsus Leads Latest Fundraising with $125 Million Private Placement
Tarsus Pharmaceuticals led recent ophthalmic fundraising efforts with a $125 million private placement for clinical development and commercial activities. Financing announced in the past four weeks...
8/20/2026
CataractDealsDry EyeGlaucomaLaserNewsletterRetina
IPG Photonics to Acquire Lumibird Medical for $342.3 Million
IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million (US $342.3 million), both companies announced July 16. A contingent earnout consideration of up to an add...
8/20/2026
AllergyCataractChinaDealsDiagnosticDry EyeEuropeFundusGene TherapyGlaucomaIOLIndustryLow VisionMyopiaNewsletterPharmaPresbyopiaRefractiveRegulationRetinaSurgical
August 2026 Ophthalmic News Briefs
Bausch + Lomb announced July 16 that it had launched the EyeGility Inserter preloaded IOL delivery system in the US. The inserter is available now with the enVista Aspire intermediate-optimized mon...
8/14/2026
BreakingCataractDry EyeGlaucomaIOLOcular CancerPharmaRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for Alcon, Tarsus, Immunocore, Harrow, Sight Sciences, and ANI
Alcon reported Aug. 10 that its Q2-2026 net sales totaled $2.8 billion, an 8 percent increase over $2.6 billion in Q2-2025. Alcon also announced that it had discontinued work on the PowerVision Flu...
8/14/2026
BreakingDealsDry EyeEurope
Italy’s Alfasigma to Acquire Nordic Pharma, Maker of Lacrifill Canalicular Gel
Italian pharmaceutical company Alfasigma announced Aug. 11 that it would acquire 100 percent of the shares of Nordic Group BV (Nordic Pharma) and its subsidiaries from Sever Life Sciences. Financia...
8/7/2026
BreakingDealsDry EyePharmaRetina
Tarsus to Acquire Alkeus Pharmaceuticals in Deal Worth up to $800 Million
Tarsus Pharmaceuticals, maker of Xdemvy, announced Aug. 6 that it would acquire Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million. Under the deal, Tarsus will pay $450 milli...
8/7/2026
BreakingDealsDry EyePharma
Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye
Harrow, of Nashville, Tennessee, announced Aug. 6 that it would acquire global rights to Tyrvaya (varenicline) nasal spray for dry eye from Viatris. Under the deal, Harrow will pay $30 million up f...
7/31/2026
BreakingCataractCornealDry EyeGene TherapyGlaucomaIOLMIGSPharmaRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, and Glaukos
Bausch + Lomb reported July 29 that its Q2-2026 revenue was $1.4 billion, a 9 percent increase over $1.3 billion in Q2-2025, driven by a 64 percent increase in implantables, including a 175 percent...
7/24/2026
BreakingCataractDealsDry EyeGlaucomaLaserRetina
IPG Photonics to Acquire Lumibird Medical for €300 Million
IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million (US $342.3 million), both companies announced July 16. A contingent earnout consideration of up to an add...
7/21/2026
BiosimilarsCornealDiagnosticDry EyeFundingGene TherapyNewsletterRetina
Ollin Leads Latest Fundraising with $330 Million in Series B Financing
Ollin Biosciences led recent ophthalmic fundraising efforts with $330 million in a Series B round to advance its candidates for retinal and thyroid eye disease. Financing announced in the past four...
7/21/2026
CataractDiagnosticDry EyeEmergingNewsletterPharmaRetina
Emerging Companies Pursuing Ophthalmic Indications, July 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
7/21/2026
CataractClinical TrialDry EyeGene TherapyNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
7/17/2026
BreakingDealsDry EyeRetinaSurgical
Tarsus Acquires iRenix, Developer of Pre-procedure Ocular Antiseptic Candidate
Tarsus Pharmaceuticals announced July 8 that it had acquired iRenix Medical, of Palo Alto, California, developer of IRX-101, an investigational ocular antiseptic. Tarsus said it would pay approxima...
7/17/2026
BreakingChinaDry EyeRegulation
Hengrui’s Cyclosporine Eye Drop Formulation for Dry Eye Gains Approval in China
China’s Hengrui Pharmaceuticals and Germany’s Novaliq announced June 30 that China’s National Medical Products Administration had approved Heng Yi (0.1% cyclosporine ophthalmic solution) for dry ey...
7/10/2026
BreakingDry EyeStudy
Researchers Develop Dry Eye Candidate Powered by Spinach and Light
Researchers in Singapore have developed a spinach-derived nanotechnology that enables corneal cells to produce a key antioxidant molecule when exposed to ambient light. The team at the National Uni...
6/26/2026
BreakingDry EyeRetina
Scope Health Adds Vision Support and Eye Comfort Eyetamins to its Optase Product Line
Scope Health, of New York, announced June 17 that it had added Eyetamins Vision Support and Eye Comfort versions to its Optase line of eyelid hygiene and ocular lubricant products. The Eye Comfort ...
6/26/2026
BreakingDry EyePharma
Ocusoft Introduces Retaine Ultra PF Preservative-Free Artificial Tears
Ocusoft, of Rosenberg, Texas, announced on June 17 the launch of Retaine Ultra PF, a lubricating eye drop available in a preservative-free multi-dose bottle. Its active ingredients include polyethy...
6/19/2026
BreakingCornealDry EyeRegulation
TearSolutions Gains Orphan, Fast Track Status for Lacripep in Neurotrophic Keratitis
TearSolutions announced June 2 that the US FDA had granted orphan drug and fast track designations for its synthetic peptide eye drop candidate Lacripep in neurotrophic keratitis (NK). NK is a rare...
6/18/2026
CataractChinaDry EyeGlaucomaNewsletterRetina
Regulatory Changes, Off-Brand Competition Reshape Ophthalmic Market in China
Continued change is shifting the dynamics of the ophthalmic market in China, boosting revenue growth in some sectors while slowing it in others. Changes are both regulatory and competitive. Regulat...
6/18/2026
Clinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, June 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
6/18/2026
DiagnosticDigitalDry EyeEmergingGene TherapyMicroscopesNewsletterRetinaSurgicalThyroid Eye Disease
Emerging Companies Pursuing Ophthalmic Indications, June 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
6/12/2026
AllergyBreakingDry EyePharma
Harrow Relaunches Verkazia in the US for Vernal Keratoconjunctivitis
Harrow reported June 10 that it had relaunched Verkazia (cyclosporine ophthalmic emulsion, 0.1%) in the US for the treatment of vernal keratoconjunctivitis (VKC). VKC is a serious allergic eye dise...
6/12/2026
BreakingDry Eye
Bausch + Lomb Launches Blink Triple Care Preservative Free Drops in US
Bausch + Lomb announced June 1 the US launch of Blink Triple Care Preservative Free eye drops. The lipid- and water-based formula combines a natural oil—to help keep tears from evaporating too quic...
5/29/2026
BreakingDry Eye
Video Series from World Council of Optometry and Alcon Summarizes TFOS DEWS III
The World Council of Optometry (WCO) and Alcon have released a series of three videos to help eye care professionals understand and apply recommendations from the updated Dry Eye Workshop III (DEWS...
5/15/2026
BreakingDeviceDry EyeGlaucomaPharmaPresbyopiaRevenue
Q1-2026 Ophthalmic Revenue Roundup for Tarsus, Sight Sciences, and Lenz
Tarsus Pharmaceuticals, of Irvine, California, reported May 6 that its Q1-2026 revenue for Xdemvy was $145.4 million, an 85 percent increase over $78.3 million in Q1-2025. Xdemvy (lotilaner ophthal...
5/14/2026
DiagnosticDry EyeGlaucomaNewsletterRegulation
Select US FDA Approvals and Clearances in April 2026
The US FDA’s ophthalmic device division granted clearance to four devices using the 510(k) pathway in April 2026, according to the agency’s database. Retmap received clearance for its RM Electrode,...
5/14/2026
BiosimilarsCataractCornealDealsDry EyeEuropeIndustryMyopiaNewsletterPresbyopiaRegulationRetinaSurgical
May 2026 Ophthalmic News Briefs
Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...
5/1/2026
BreakingCornealDry EyePharmaStudy
Formosa, Singapore Eye to Explore New Treatments for Corneal, Ocular Surface Disease
Taiwan’s Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) have teamed up to address unmet needs in corneal and ocular surface disease, Formosa announced April 30. The partner...
4/21/2026
Dry EyeGlaucomaNewsletter
Nanodropper Bottle Tip Adaptor Goes from Simple Idea to Global Product
Mu Medical has been turning heads for years with claims that its Nanodropper bottle tip adaptor cuts typical eye drop volume more than 60 percent, resulting in a single medicine bottle lasting seve...
4/21/2026
ASCRSCornealDiagnosticDry EyeGlaucomaIOLMeetingNewsletterOCTSurgical
Meeting-Related Launches Include Range of Ophthalmic Products
Several ophthalmic companies launched products at the 2026 annual meeting of the American Society of Cataract and Refractive Surgery, held April 10-13 in Washington, DC. Market Scope will be coveri...
4/21/2026
BiosimilarsCataractCell TherapyChinaClinical TrialCornealDiagnosticDigitalDry EyeIOLIndiaIndustryMicroscopesNewsletterPharmaRegulationRetina
April 2026 Ophthalmic News Briefs
Swiss ophthalmic diagnostics company Haag-Streit announced March 31 the global launch of its Metis 3D Digital Heads-Up Module (Metis HU). The system was launched in the US in October 2025. Metis HU...
4/17/2026
BreakingDry EyePharmaRegulation
KC Pharmaceuticals Recalls 3.1 Million Eye Drop Bottles over Sterility Concerns
The US FDA reported in March that more than 3.1 million bottles of over-the-counter eye drops sold at major US retailers—including CVS, Walgreens, Kroger, and Rite Aid—had been recalled over steril...
4/17/2026
BreakingDealsDiagnosticDry EyeLaser
Lumibird to Acquire Malaysian Distributor, Establish Southeast Asian Hub
French company Lumibird announced April 8 that it had signed an agreement to acquire its long-term distribution partner Biz Medic, of Kuala Lumpur, Malaysia. The company said, however, that it was ...
4/17/2026
BreakingDry Eye
Nordic Pharma Now Includes Cannulas with Lacrifill, Marks US Milestone
Dutch drugmaker Nordic Pharma announced April 9 that it is now shipping cannulas along with its syringes of its Lacrifill canalicular gel for dry eye. The company said it made the move in response ...
4/10/2026
BreakingCornealDry Eye
Cellution Launches OptiCover Amniotic Graft at ASCRS Meeting
Cellution Biologics launched its OptiCover amniotic graft for ocular use at the 2026 meeting of the American Society of Cataract and Refractive Surgery (ASCRS), which ran April 10-13 in Washington,...
3/27/2026
BreakingChinaDealsDry EyeRegulation
Regulators in China Approve Lotilaner Drops, Triggering $15 Million Payment to Tarsus
Tarsus Pharmaceuticals announced March 23 that regulators in China had approved TP-03 (lotilaner ophthalmic solution) 0.25%, its mite-killing treatment targeting Demodex blepharitis that is markete...
3/24/2026
Dry EyeNewsletterPharmaRegulation
US FDA Again Rejects Aldeyra’s Reproxalap for Dry Eye, Citing Trial Failures
Aldeyra Therapeutics reported March 17 that the US FDA had issued a third complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap in dry eye disease. Alde...
3/24/2026
AllergyDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, March 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
3/20/2026
BreakingDry EyePharmaRegulation
US FDA Again Rejects Aldeyra’s Reproxalap for Dry Eye, Citing Trial Failures
Aldeyra Therapeutics reported March 17 that the US FDA had issued a third complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment for dry e...
3/13/2026
BreakingDry EyeGlaucomaRefractiveRevenueSurgical
2025 Ophthalmic Revenue Roundup for STAAR Surgical and Sight Sciences
STAAR Surgical reported March 3 that its net sales in 2025 were $239.4 million, a 23.7 percent decline from $313.9 million in 2024. Q4-2025 net sales were $57.8 million, an 18.1 percent increase ov...
2/27/2026
BreakingCataractDry EyeOcular CancerPharmaRetinaRevenueSurgical
2025 Ophthalmic Revenue Roundup for Alcon, Apellis, Tarsus, and Immunocore
Alcon reported Feb. 24 that its full year 2025 net sales totaled $10.3 billion, a 5 percent increase over $9.8 billion in 2024. Q4-2025 sales were $2.7 billion, a 9 percent increase over $2.5 billi...
2/23/2026
Dry EyeNewsletterRegulationRetinaThyroid Eye Disease
PDUFA Dates for Ophthalmic Drug Candidates, February 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
2/23/2026
Cell TherapyCornealDealsDry EyeFundingGene TherapyIndiaNewsletterPresbyopiaRetina
BioAge Leads Latest Ophthalmic Fundraising with $115 Million Offering
BioAge led recent ophthalmic fundraising efforts with a $115 million upsized public offering to advance an oral treatment candidate for DME. Financing announced in the past four weeks totaled $308....
2/23/2026
Dry EyeEmergingNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, February 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
2/23/2026
CataractClinical TrialCornealDealsDiagnosticDry EyeIOLNewsletterRefractiveRegulationRetinaSurgicalUveitis
February 2026 Ophthalmic News Briefs
Belgian investment company Groupe Bruxelles Lambert (GBL) reported Feb. 9 that it would invest 500 million euros (US $594 million, calculated on Feb. 11, 2026) in UK-based ophthalmic company Rayner...
2/20/2026
BreakingCataractCornealDry EyeGlaucomaIOLRevenueSurgical
2025 Ophthalmic Revenue Roundup for Bausch + Lomb and Glaukos
Bausch + Lomb reported Feb. 18 that its 2025 revenue totaled $5.1 billion, a 6 percent increase over $4.8 billion in 2024. The company’s Q4-2025 revenue was $1.4 billion, a 10 percent increase over...
2/12/2026
BreakingDry EyeEurope
Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eye in Europe
Dutch drugmaker Nordic Pharma announced Feb. 5 the European launch of Lacrifill canalicular gel for dry eye. The treatment gained CE marking in April 2025. Lacrifill is a cross-linked hyaluronic ac...
2/6/2026
BreakingCataractDry EyePharmaRegulationRetina
Harrow Ends Compounded Product Sales in California, Plans to Sell All Products Under Harrow Label
Harrow reported Feb. 2 that it had stopped selling compounded products in California through its ImprimisRx subsidiary on Feb. 1, after settling a disciplinary action brought by the California Boar...
1/28/2026
Dry EyePress Release
Three New Prescription Drugs Reshape the US Dry Eye Pharmaceutical Market, According to Market Scope
Three recently launched prescription therapies are rapidly redefining the competitive landscape of the US dry eye pharmaceutical market and are expected to drive significant revenue growth over the...
1/21/2026
Dry EyeNewsletterPresbyopiaRegulationRetina
PDUFA Dates for Ophthalmic Drug Candidates, January 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
1/21/2026
Dry EyeNewsletterRegulation
US FDA Extends Action Date on Aldeyra’s Reproxalap to March 2026
Aldeyra Therapeutics reported Dec. 15 that the US FDA had extended the Prescription Drug User Fee Act (PDUFA) target action date for dry eye drop candidate reproxalap to March 16, 2026. The company...
1/21/2026
DealsDiagnosticDry EyeEuropeNewsletterRetina
2025 in Review: EssilorLuxottica Entrenches Ophthalmic Strategy with 2025 Deals
EssilorLuxottica reported Dec. 12 that it had acquired Signifeye, a network of 15 eye centers and clinics in the Flanders region of Belgium. The transaction is expected to close by Q1-2026. No fina...
1/9/2026
BreakingCornealDry EyeIndustry
Okyo Pharma Appoints Industry Veteran Robert J. Dempsey as CEO
London’s Okyo Pharma announced Jan. 5 that ophthalmic industry veteran Robert J. Dempsey would assume the role of chief executive officer. Gary S. Jacob, PhD, will transition to chief development o...
1/9/2026
BreakingDry EyeRegulationRetina
US FDA Grants Breakthrough Status to Oculis’ Privosegtor for Optic Neuritis
Swiss company Oculis announced Jan. 6 that the US FDA had granted breakthrough therapy designation to Privosegtor, its treatment candidate for optic neuritis. Privosegtor is a peptoid small molecul...
1/2/2026
BreakingClinical TrialCornealDry EyeRegulation
US FDA Gives Green Light to Trial of Viatris’ Gene Therapy Candidate for NK
Viatris reported on Dec. 18 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of MR-146, a gene therapy candi...
1/2/2026
BreakingDeviceDry EyeIndustry
Meibum Scientific Appoints Ryan S. Bleeks as Interim CEO
Meibum Scientific, of Brentwood, Tennessee, announced Dec. 2 that it had appointed Ryan S. Bleeks as interim chief executive officer to lead the commercialization of dry eye treatment devices Bleph...
12/26/2025
BreakingDry EyeGenericsPharmaRegulation
Amneal Gains US FDA Approval for Generic Version of Restasis for Dry Eye
Amneal Pharmaceuticals announced Dec. 1 that it had received US FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. C...
12/19/2025
BreakingDry EyePharmaRegulation
US FDA Extends Action Date on Aldeyra’s Reproxalap to March 2026
Aldeyra Therapeutics reported Dec. 15 that the US FDA had extended the Prescription Drug User Fee Act (PDUFA) target action date for dry eye drop candidate reproxalap to March 16, 2026. The new dru...
12/16/2025
Dry EyeNewsletterPharma
New Products Power Revenue Growth in Dry Eye Pharmaceuticals
Three new drugs shaking up the dry eye pharma market in the US are poised to drive revenue growth in the next five years. Xdemvy (lotilaner ophthalmic solution), from Tarsus Pharmaceuticals, has be...
12/16/2025
DeviceDry EyeNewsletter
Dry Eye Device Field Gets More Crowded With Product Launches
The dry eye procedure market is relatively small, but barriers to entry are low, and that is attractive for new competitors. Asian companies, from China and South Korea, launched new machines in th...
12/16/2025
AcquisitionsDealsDry EyeNewsletter
Iolyx Licenses Autoimmune Dry Eye Candidate to Théa in Deal Worth Up to $280 Million
Iolyx Therapeutics announced Dec. 3 that it had granted rights worldwide, excluding Asia, to France’s Laboratoires Théa to develop and commercialize ILYX-002, an immune-modulating eye drop candidat...
12/16/2025
CornealDry EyeFundingNewsletterRetina
Belite Leads Latest Ophthalmic Fundraising with $350 Million Offering
Belite Bio led recent ophthalmic fundraising efforts with a $350 million offering to prepare for commercial-ization of oral tinlarebant for geographic atrophy and Stargardt. Financing announced in ...
12/5/2025
BreakingCataractDealsDry EyeFLACSGlaucomaIOLPharmaSurgical
Bausch + Lomb Outlines Growth Plans, Driven by Deep Pipeline
Bausch + Lomb used its investor day on Nov. 13 to lay out how it plans to produce growth of 6 to 8 percent in its surgical segment and 5 to 7 percent in its pharmaceutical, consumer, and contact le...
12/5/2025
BreakingDealsDry Eye
Iolyx Licenses Autoimmune Dry Eye Candidate to Théa in Deal Worth Up to $280 Million
Iolyx Therapeutics announced Dec. 3 that it had granted rights worldwide, excluding Asia, to France’s Laboratoires Théa to develop and commercialize ILYX-002, an immune-modulating eye drop candidat...
11/26/2025
BreakingDealsDry Eye
Cartwheel to License ClearSight’s OTC Pink Eye Treatment
Cartwheel, of Boston, Massachusetts, reported Nov. 12 that it had signed a letter of intent to license ClearSight Therapeutics’ over-the-counter (OTC) pink eye treatment beginning in 2027. ClearSig...
11/19/2025
AAOCataractDry EyeMeetingNewsletterRetina
Harrow Takes Unconventional Path, Sees Soaring Revenue Growth
Harrow is making waves in ophthalmology. Product acquisitions, rapid growth, and breaking with convention are all part of CEO Mark Baum’s blueprint for building the first major new US ophthalmic co...
11/21/2025
BreakingCornealDry EyeSurgical
Cellution Launches AmnioPlast Allografts in US for Ocular Surface Repair
Cellution Biologics announced Nov. 19 the US launch of its AmnioPlast 1 monolayer and AmnioPlast Double dual-layer dehydrated amnion membrane allografts for ocular surface repair. The Roswell, Geor...
11/19/2025
Dry EyeNewsletterPresbyopiaRegulationRetina
PDUFA Dates for Ophthalmic Drug Candidates
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
11/19/2025
Dry EyeFundingGene TherapyGlaucomaNewsletterRetina
AAVantgarde Leads Latest Ophthalmic Fundraising with $141 Million in Series B
AAVantgarde Bio led recent ophthalmic fundraising efforts with $141 million in Series B funding to advance its retinal gene therapy pipeline. Financing announced in the past four weeks totaled $488...
11/19/2025
AAOCataractDiagnosticDry EyeEquipmentGlaucomaLaserMeetingNewsletterRetina
Numerous New Products Showcased at 2025 AAO Meeting
More than 16 thousand people attended the 2025 meeting of the American Academy of Ophthalmology, held Oct. 17-20 at the Orange County Convention Center in Orlando, Florida. Sixty percent of them we...
11/19/2025
ChinaCornealDealsDiagnosticDry EyeEmergingNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, November 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
11/14/2025
BreakingDry EyeFLACSGlaucomaIOLLaserMIGSOcular CancerPharmaRefractiveRetinaRevenueSurgical
Q3-2025 Ophthalmic Revenue Roundup for Alcon, Santen, Immunocore, STAAR, Harrow, and Five Others
Alcon reported Nov. 11 that its Q3-2025 net sales totaled $2.6 billion, a 6 percent increase over $2.4 billion in Q3-2024. Surgical net sales for implantables, consumables, and equipment/other were...
11/7/2025
BiosimilarsBreakingDry EyeGlaucomaIOLLaserPresbyopiaRetinaRevenueSurgicalThyroid Eye Disease
Q3-2025 Ophthalmic Revenue Roundup for Amgen, AbbVie, Hoya, Glaukos, Apellis, Astellas, and Four Others
Amgen, of Thousand Oaks, California, reported Nov. 4 that its Q3-2025 revenue from Tepezza was $560 million, a 15 percent increase over $488 million in Q3-2024. The total consisted of $518 million ...
10/31/2025
BreakingCataractDry EyeIOLPharmaRetinaRevenueSurgical
Q3-2025 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, Regeneron, Novartis
Bausch + Lomb reported Oct. 29 that its Q3-2025 revenue totaled $1.3 billion, a 7 percent increase over $1.2 billion in Q3-2024. Ophthalmic pharmaceuticals segment revenue was $330 million, an 8 pe...
10/23/2025
Cell TherapyCornealDiagnosticDry EyeFundingGene TherapyGlaucomaMyopiaNewsletterPharmaRetina
Ocular Tx Leads Latest Ophthalmic Fundraising with $475 Million Offering
Ocular Therapeutix led recent ophthalmic fundraising efforts with a $475 million underwritten public offering to advance its Axpaxli IVT implant candidate for retinal disease. Financing announced i...
10/23/2025
Dry EyeMyopiaNewsletterRegulation
PDUFA Dates for Ophthalmic Drug Candidates, October 2025
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
10/23/2025
BiosimilarsCataractChinaCornealDealsDiagnosticDry EyeEuropeGene TherapyGenericsGlaucomaIndiaIndustryMIGSNewsletterPharmaPresbyopiaRegulationRetinaSurgical
October 2025 Ophthalmic News Briefs
Biotech Healthcare announced Sept. 23 that it had launched the Optiflex Xtense Comfort Plus extended-depth-of-focus (EDOF) intraocular lens at the ESCRS 2025 congress in Copenhagen, Denmark. Biotec...
10/3/2025
BreakingDry EyePharma
Harrow to Expand Access for All Program to Full Drug Portfolio
Harrow, of Nashville, Tennessee, reported Sept. 25 that it was expanding its Vevye Access for All program to the rest of its portfolio, making it easier and more affordable for patients to obtain t...
10/3/2025
BreakingDealsDry EyeEuropeGlaucomaIndiaRetina
Visufarma Becomes Part of India’s Lupin Limited
Visufarma BV, of the Netherlands, will become part of India-based Lupin Limited following Visufarma’s acquisition by a Lupin subsidiary. Visufarma has been owned by GHO Capital Partners, of London,...
9/26/2025
BreakingDiagnosticDry Eye
Topcon Launches Tera Imager for Detection and Management of Dry Eye
Topcon Healthcare announced Sept. 18 the launch of its Tera Dry Eye Imager, a multimodal platform designed to detect, grade, and manage dry eye disease. Topcon said Tera pairs automation with high-...
9/22/2025
BiosimilarsClinical TrialCornealDealsDiagnosticDry EyeEuropeFundingGene TherapyGlaucomaIndustryNewsletterRefractiveRegulationRetinaSurgical
September 2025 Ophthalmic News Briefs
The UK-based National Institute for Health and Care Excellence (NICE) announced Sept. 11 that it had approved idebenone (marketed as Raxone by Chiesi Pharmaceuticals) for the treatment of Leber her...
9/12/2025
BreakingDry Eye
Mina Massaro-Giordano, MD, to Lead New Dry Eye Service at NYU Langone
NYU Langone Health announced Aug. 28 that dry eye specialist Mina Massaro-Giordano, MD, had been appointed to lead its newly established Dry Eye Service in the Department of Ophthalmology. Massaro-...
8/29/2025
BiosimilarsBreakingDiagnosticDry EyeLaserMyopiaRetinaRevenue
Quarterly Ophthalmic Revenue Roundup for Santen, Lumibird, Biogen, and Xbrane
Japan’s Santen Pharmaceutical reported Aug. 7 that its revenue for the quarter ended June 30, 2025, the first quarter of its fiscal year, was ¥68.7 billion ($475.6 million, converted on June 30, 20...
8/20/2025
Clinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, August 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
8/20/2025
DiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, August 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
8/20/2025
BiosimilarsClinical TrialDealsDry EyeEuropeGene TherapyGlaucomaIndustryInstrumentsLaserNewsletterRegulationRetinaSurgical
August 2025 Ophthalmic News Briefs
Glaukos announced during its earnings call on July 30 that it had acquired Mobius Therapeutics, of St. Louis, Missouri, whose lead compound, Mitosol, is the only FDA approved ophthalmic formulation...
8/15/2025
BreakingCataractDry EyeGlaucomaLaserOcular CancerPharmaRetinaRevenueSurgical
Q2-2025 Ophthalmic Revenue Roundup for Tarsus, Immunocore, Harrow, ANI, Sight Sciences, and Iridex
Tarsus Pharmaceuticals, of Irvine, California, reported Aug. 6 that its Q2-2025 Xdemvy net product revenue was $102.7 million, a 152 percent increase over $40.8 million in Q2-2024. The company said...
8/8/2025
BiosimilarsBreakingDry EyeGlaucomaIOLPresbyopiaRetinaRevenueSurgicalThyroid Eye Disease
Q2-2025 Ophthalmic Revenue Roundup for Regeneron, Amgen, AbbVie, Hoya, and Ocular Therapeutix
Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2025 US revenue for Eylea HD and Eylea 2 mg was $1.15 billion, a 25 percent decrease from $1.53 billion in Q2-2024. Eylea HD accounted...
8/1/2025
BreakingDry EyePharma
Alcon Launches Tryptyr (Acoltremon) Drops for Dry Eye in US
Alcon announced July 29 the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% to treat the signs and symptoms of dry eye. Tryptyr is a first-in-class TRPM8 agonist, dose...
7/25/2025
BreakingClinical TrialDry Eye
Viatris’ Phase III Blepharitis Ointment Candidate Fails to Reach Primary Endpoint
Viatris announced July 18 that a Phase III trial of pimecrolimus 0.3% (MR-139) ophthalmic ointment in blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks ...
7/22/2025
CornealDiagnosticDry EyeMeetingNewsletterPharmaRetinaSurgical
EyeDura Wins Two Octane Awards for Sustained-Release Eye Drop Platform
EyeDura Therapeutics earned the judges’ top award during Octane’s capital and growth company presentations, which spotlighted early-stage, high-potential ophthalmic ventures. The company was a favo...
7/22/2025
Cell TherapyClinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
7/22/2025
DiagnosticDry EyeNewsletter
DEWS III Report Updates Guidelines for Diagnosis and Management of Dry Eye
The Tear Film and Ocular Surface Society (TFOS) has released DEWS III, its third set of reports exploring the diagnosis and management of dry eye disease. The findings of the TFOS Dry Eye Workshop ...
7/22/2025
BiosimilarsCornealDry EyeMyopiaNewsletterPresbyopiaRegulationRetina
PDUFA Dates for Ophthalmic Drug Candidates, July 2025
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
7/22/2025
BiosimilarsCataractCell TherapyChinaClinical TrialDealsDiagnosticDry EyeEuropeFundingFundusGene TherapyGlaucomaNewsletterPharmaPresbyopiaRegulationRetinaSurgical
July 2025 Ophthalmic News Briefs
Hoya Vision Care announced June 2 that it had acquired Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. Financial...
7/11/2025
BreakingChinaDry EyeRegulation
Chinese Regulators Approve Perfluorohexyloctane Drops for Dry Eye with MGD
China’s Hengrui Pharmaceuticals and Germany’s Novaliq announced July 8 that China’s National Medical Products Administration had approved Heng Qin (perfluorohexyloctane eye drops) for dry eye assoc...
7/11/2025
BreakingDry Eye
Rain Eye Drops Launches Dispensing Tool for Single-Use Vials to its Customers
Rain Eye Drops, of Las Vegas, Nevada, reported July 8 the launch of its RainDrop Dispenser Aid, a tool designed to help users apply eye drops from single-use vials more easily and accurately. The c...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.